Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist
نویسندگان
چکیده
منابع مشابه
Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
UNLABELLED Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation. We describe an unusual case of a patient with a known pituitary macroadenoma presenting with acute-onset third nerve palsy and headache secondary to tumour e...
متن کاملPulsatile administration of gonadotropin-releasing hormone agonist to gilts actively immunized against gonadotropin-releasing hormone.
Sexually mature gilts (n = 20) were actively immunized against GnRH. Primary and booster immunizations of GnRH conjugated to bovine serum albumin induced production of antibodies in all gilts. Nineteen of the gilts became acyclic with suppressed concentrations of gonadotropins and estradiol. Intravenous challenges with 100 micrograms GnRH and 5 micrograms D-(Ala6, des-Gly-NH2(10)) ethylamide Gn...
متن کاملLuteal phase support with gonadotropin-releasing hormone agonist.
Kung et al authored a valuable article entitled “Luteal phase support with decapeptyl improves pregnancy outcomes in ICSI with basal FSH >8 mIU/mL or mature oocytes 3”. This retrospective study enrolled 240 patients who underwent intracytoplasmic sperm injection (ICSI). One hundred and forty-seven patients were in the decapeptyl group and 93 patients were in the control group. The authors inves...
متن کاملRaloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density
OBJECTIVES To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration. METHODS Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4 weeks, for 48 weeks. Bone mineral density (BMD) was evaluated at admission, and after 12 treatment...
متن کاملAdult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone
PURPOSE There is controversy surrounding the growth outcomes of treatment with gonadotropin-releasing hormone agonist (GnRHa) in central precocious puberty (CPP). We analyzed height preservation after treatment with GnRHa with and without growth hormone (GH) in girls with CPP. METHODS We reviewed the medical records of 82 girls with idiopathic CPP who had been treated with GnRHa at Severance ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Hypertension
سال: 2017
ISSN: 1524-6175
DOI: 10.1111/jch.13052